Cyclin-dependent kinase (CDK4/6) inhibitors in combination with endocrine therapy are currently the optimal first line treatment for hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) non-amplified metastatic breast cancer (MBC). However, not all patients benefit from this treatment and all patients will inevitably progress. Identifying therapeutic strategies in this setting is therefore of immediate clinical importance. We present an overview of the mechanisms of resistance to CDK4/6 inhibitors and review potential biomarkers that may guide therapy selection. We also discuss the use of CDK4/6 inhibitors in the context of non-HR-positive/HER2-non-amplified breast cancer and in combination with therapies other than endocrine therapy.
INTRODUCTION
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors in combination with endocrine therapy have been shown to improve progression free survival (PFS) in hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) non-amplified metastatic breast cancer (MBC) compared with endocrine therapy alone in both the first and second line treatment settings. This combination represents the current standard of care in an increasing number of countries, and has Food and Drug Administration (FDA) approval in the United States (US) and Pharmaceutical Benefits Scheme (PBS) approval in Australia.
Currently estrogen receptor (ER) positivity and HER2 negativity are the only biomarkers used to select patients with MBC for combination endocrine therapy and CDK4/6 inhibitor treatment. However, clinical trials suggest that a proportion of patients have de novo resistance to this treatment combination, and the vast majority of patients will inevitably develop resistance. The strategies to combat resistance to these combination treatments are not yet defined and represent the next major clinical challenge in ER-positive breast cancer. Further research is needed to identify predictive biomarkers of response and new therapeutic strategies for patients who progress on this combination therapy. In this review, we explore the mechanisms of resistance F I G U R E 1 Signaling pathways in ER-positive breast cancer. AI, aromatase inhibitor; AKT, serine/threonine protein kinase; CDK4/6, cyclin-dependent kinase 4/6; E2F, E2F transcription factors; EGFR, epidermal growth factor receptor; ER, estrogen receptor; ERK, extra-cellular signal-related kinase; FGFR, fibroblast growth factor receptor; IGFR, insulin growth factor receptor; HER2, human epidermal growth factor receptor 2; MEK, mitogen-activated protein kinase/extra-cellular signal-regulated kinase; mTOR, mammalian target of rapamycin; Pi3K, phosphatidylinositol-3 kinase; RAS, RAS gene; Rb, retinoblastoma; SERDs, selective estrogen receptor degraders to CDK4/6 inhibitors and review potential biomarkers that may guide therapy selection. We also consider treatment options for patients who progress following treatment with a CDK4/6 inhibitor, the use of CDK4/6 inhibitors in the context of non-HR-positive/HER2-nonamplified breast cancer, and combinations with therapies other than endocrine therapy.
BIOMARKERS OF RESPONSE TO CDK4/6 INHIBITORS
CDK4/6 inhibitors are effective in both endocrine-sensitive and endocrine-resistant breast cancer. This has been demonstrated in preclinical studies, and then subsequently in the seminal clinical trials, which have included treatment-naïve patients as well as patients who had relapsed or progressed on endocrine therapy. [1] [2] [3] [4] [5] [6] [7] [8] A core reason underlying the efficacy of CDK4/6 inhibitors is their ability to overcome some of the mechanisms that mediate endocrine-resistance, although the eventual progression of disease in the majority of patients treated points to the existence or development of overlapping resistance mechanisms.
Potential predictive biomarkers of response have been evaluated for CDK4/6 inhibitors. Other than ER and retinoblastoma (Rb) positivity, the results have been disappointing in general with none having been clinically validated in patients with HR-positive, HER2-non-amplified breast cancer to date. Dysregulation of the cyclin-CDK-Rb axis by upregulation of cyclin-CDK activity and/or abrogation of suppressors are features of many tumor types, including ER-positive breast cancer. In this cancer, growth is driven by estradiol, which consequently drives cellular proliferation, partly through the increase in levels of cyclin D1 and CDK4/6 activity. 9 Figure 1 shows the interacting signaling pathways in ER-positive, HER2-non-amplified breast cancer and therapeutic targets.
Biomarker studies performed in the PALOMA-2 trial included central blinded analysis on the immunohistochemistry for ER, phosphorylated Rb (pRb), p16, cyclin D1 and Ki-67. A PFS improvement in the palbociclib arm was observed in patients with tumors in all ER quartiles, in patients that were Rb-positive (> 90% of intent-to-treat population (ITP); 24.2 vs. 13.7 months; HR, 0.53; P < 0.0001), and in p16-positive patients (85% ITP; 24.8 vs. 13.8 months; HR, 0.52; P < 0.0001). The vast majority of patients were found to be cyclin D1-positive (97%), and the benefit of adding palbociclib did not vary with H-score. 10 Similarly, higher expression of genes in the cyclin D-CDK4/6-Rb pathway did not correlate with greater benefit from palbociclib. 11 One study in patients with HR-positive MBC evaluated the association between response to CDK4/6 inhibitors in second line use and beyond and PIK3CA and TP53 mutations in metastatic tumor DNA. 12 No significant difference in PFS was seen among patients with PIK3CA mutations (7.1 vs. 9.7 months; P = 0.28) or with any alteration in the PI3K/Akt/mTOR pathway (8.2 vs. 9.3 months; P = 0.40). Patients who had TP53 mutations or complex tumor genomics had a trend toward shorter PFS, however statistical significance was not reached possibly due to the small number of patients in this subgroup.
A study of baseline tumor tissue samples from patients in the PALOMA-3 trial found that patients with low tumor cyclin E expression experienced a greater benefit from palbociclib compared to patients with high expression (median PFS 14.1 vs. 7.6 months, P = 0.0024).
However, other cell cycle genes did not show any interaction as a biomarker, with all subgroups deriving similar benefit from palbociclib compared to placebo. 13 Studies of baseline circulating tumor DNA (ctDNA) and tumor tissues from the PALOMA trials found no link between response to palbociclib and PIK3CA mutational status. 3, 10 In contrast, when sequential plasma samples at baseline and day 15 were studied in a subset of patients in the PALOMA-3 study, a relative decrease in PIK3CA ctDNA strongly predicted for a PFS improvement with palbociclib plus fulvestrant (HR 3.94; 95% CI 1.61-9.64; P = 0.0013). 14 alterations). 15 In a small study, the longitudinal mutational landscape was evaluated in the ctDNA of 15 patients who progressed during treatment with palbociclib plus endocrine therapy. There was stable and persistent incidence of PIK3CA, TP53 and ESR1 mutations before treatment and at progression. In addition, there was also a low but measurable incidence of new mutations found in other genes, and an increased rate of MYC gene amplification that may be related to drivers of CDK4/6 inhibitor-resistance. 16 Table 1 .
NOVEL THERAPEUTIC COMBINATIONS
First, there is a growing number of endocrine therapies being developed that are potentially more effective than tamoxifen, aromatase inhibitors and fulvestrant. These new endocrine therapies would make logical partners with CDK4/6 inhibitors. Next generation selective ER degraders (SERDs) currently in clinical development have been shown to be more potent than their prototype fulvestrant with activity in endocrine-resistance and ESR1 mutations. 17 Furthermore, many of these are orally bioavailable in contrast to fulvestrant, which is administered as an injection, increasing patient convenience.
One such example is elacestrant (RAD1901), which has enhanced the efficacy of both palbociclib and abemaciclib in vitro. 18 The PI3K signaling pathway is a major alternative signaling pathway that is upregulated in endocrine-resistance (Figure 1 Preclinical studies with triplet combinations of PI3K/mTOR inhibitors, CDK4/6 inhibitors and endocrine therapies have been promising, 23 forming the basis of a number of phase I clinical studies currently underway (Table 1) . [23] [24] [25] [26] [27] Initial results suggest that these combinations are feasible with manageable toxicity and showed encouraging signs of clinical activity including in some patients with prior exposure to PI3K/AKT/mTOR or CDK4/6 inhibitors. [25] [26] [27] One study found that duration of treatment was longer in patients with cyclin D amplification, possibly due to the inclusion of a CDK4/6 inhibitor. These results suggest that triplet therapy might be beneficial for patients who progress on doublet therapy or who have cyclin D amplification. 26 Entinostat is an oral, class 1, selective histone deacetylase (HDAC) inhibitor, which has been shown to inhibit ER-positive breast cancer cells and restore endocrine sensitivity as a result of the downregulation of estrogen-independent growth factor signaling pathways. 28 
RESISTANCE TO CDK4/6 INHIBITORS
Many of the preclinical studies to date have evaluated single agent resistance to CDK4/6 inhibitors, in contrast to the clinical context in which resistance occurs in combination with endocrine therapy. An important consideration is how the ER and CDK4/6 directed therapy resistance mechanisms overlap. CDK4/6 inhibition acts directly downstream of endocrine therapy and it is therefore inevitable that some mechanisms of resistance will be common to both types of treatments.
Mechanisms of endocrine-resistance have been well described, including upregulation of alternate signaling pathways, genomic and epigenetic aberrations. [38] [39] [40] Rb is maintained in the vast majority of ER-positive breast cancer, and in most cases functional Rb protein is retained through the development of endocrine-resistance, 41 rendering these tumors amenable to CDK4/6 inhibition. In addition, the incidence of Rb gene deletion/mutation is very rare (3.9%) in ERpositive breast cancer. 42 While there have been preclinical studies demonstrating that Rb loss is a mechanism for resistance to CDK4/6 inhibition, 43, 44 the jury is still out as to whether Rb is a predictive biomarker for CDK4/6 inhibitor response as there are studies in other cancer types to suggest that functional Rb is not an absolute requirement for CDK4/6 inhibitors to be effective. 45 Other proposed mechanisms of resistance to CDK4/6 inhibitors include the upregulation of CDK4 or CDK6. In one study, CDK4 T172-phosphorylation was found to correlate with sensitivity to palbociclb, and an 11-gene expression signature that predicted CDK4 modification profiles of breast tumors and cell lines correlated with palbociclib response. 46 Low levels of CDK6 expression have been shown to be positively correlated with the efficacy of ribociclib in endocrine-resistant breast cancer cell lines. 47 CDK6 has also been shown to play a role in mediating endocrine-resistance, highlighting the potential overlap in mechanisms of resistance to endocrine therapy and CDK4/6 inhibitors.
Increased expression of CDK6 have been described in fulvestrantresistant breast cancer cell lines. 48 Furthermore, high CDK6 levels in metastatic tumor tissue from two independent cohorts of breast cancer patients treated with fulvestrant (n = 45 and 46) correlated significantly with shorter PFS in patients treated with fulvestrant (median time to progression 2.5 vs. 8.2 months, P = 0.0006 and 3.4 vs. 8.9
months, P = 0.018). Treatment with palbociclib resulted in alteration of Rb protein phosphorylation and re-sensitization of the cells to fulvestrant in preclinical models. 48 
POTENTIAL TREATMENT STRATEGIES TO OVERCOME RESISTANCE TO CDK4/6 INHIBITORS
In addition to playing a role in endocrine-resistance, FGFR1 amplification has also been reported to induce resistance to fulvestrant and CDK4/6 inhibitor combinations in gain-of-function kinase library screens in cell lines. 49 The resistance phenotype was abrogated with the FGFR tyrosine kinase inhibitor lucitanib. Furthermore, in the MONALEESA-2 study, FGFR1 amplification in ctDNA was shown to correlate with early progression on ribociclib. 15 The data suggest that FGFR signaling is a mechanism of resistance to endocrine therapies with or without CDK4/6 inhibitors, with overexpression of cyclin D1
induced by both FGFR signaling and ER transcription. 49 Additionally, Table 1 ).
In another study using ribociclib-resistant breast cancer cells, dinaciclib, a pan-CDK inhibitor and GSK2334470, a 3-phoshoinositide dependent protein kinase 1 (PDK1) inhibitor was found to resensitize the resistant cells to CDK4/6 inhibitors. 51 Ribociclib plus GSK2334470 completely abrogated components of the cell cycle, including pRb, pS6, pRSK2, pCDK2, cyclin A and cyclin E, making this combination another potential strategy to overcome CDK4/6 inhibitor resistance.
Finally, higher activator protein 1 (AP-1) transcriptional activity has been demonstrated in dually tamoxifen and palbociclib-resistant cell lines. 52 The combination of palbociclib and AP-1 blockade was effective in inhibiting cell growth and reducing pRb and CDK2 levels compared to either agent alone.
TREATMENT OF HR-POSITIVE, HER2-NON-AMPLIFIED MBC FOLLOWING PROGRESSION ON A CDK4/INHIBITOR
This clinical scenario will increase in frequency as CDK4/6 inhibitors become established as the standard of care for patients with advanced ER-positive breast cancer in combination with endocrine therapy.
There are currently no treatment guidelines as to how to manage patients who progress on CDK4/6 inhibitors, even though CDK4/6 inhibitor use is most often confined to the first and second line settings.
Several studies have investigated the follow-up treatment of patients after participation in clinical trials with a CDK4/6 inhibitor. In patients studied for 9 months immediately after participation in the PALOMA-3 study, the median time to subsequent chemotherapy was significantly longer for the palbociclib arm compared to the placebo arm (252 vs. 132 days), and fewer patients in the palbociclib arm discontinued next-line treatment (33% vs. 46%), suggesting that palbociclib did not adversely affect the efficacy of subsequent treatments. 53 Similar trends were observed for post-progression treatment of patients receiving the next line of therapy immediately following participation in the PALOMA-1 trial. 54 In the MONALEESA-2 study, ribociclib plus letrozole also prolonged the time to next treatment compared to letrozole alone (24.2 vs. 16.7 months). 55 Fewer patients treated with the combination received subsequent chemotherapy compared with letrozole alone (15.8% vs. 22.4%).
In contrast, there are case studies of rapid secondary disease progression during subsequent lines of therapy following cessation of CDK4/6 inhibitors. 56 This observation has not been reported in larger CDK4/6 inhibitor clinical trials. 
OTHER CLINICAL SCENARIOS IN WHICH CDK4/6 INHIBITORS MAY PLAY A ROLE IN BREAST CANCER

Patients with central nervous system (CNS) metastases
A lower percentage of patients with HR-positive, HER2-non-amplified MBC develop brain metastases when compared with patients with triple negative breast cancer or HER2-amplified MBC. 61 However, owing to the high incidence of the HR-positive, HER2-non-amplified breast cancer sub-type, cases are still relatively common. There are no specific regulatory approved systemic agents for the treatment of HR-positive breast cancer brain metastases, and so this remains an unmet medical need. Standard local treatment options include surgery, stereotactic radiosurgery (SRS) and/or whole brain radiation therapy (WBRT). 61 There is preliminary evidence and preclinical data that ribociclib, abemaciclib and palbociclib cross the brain-blood barrier, 62, 63 with data suggesting that albemaciclib may be more efficient in crossing the blood-brain barrier compared to palbociclb. 62 Several clinical trials are ongoing to evaluate CDK4/6 inhibitors in patients with brain metastases (Table 1) . 64,65
HR-positive, HER2-amplified MBC
There have been results from three phase II clinical studies investigating the treatment of HER2-amplified MBC with palbociclib. PATRICIA assessed the efficacy of palbociclib and trastuzumab in advanced HER2-amplified breast cancer (patients had received two to four prior lines of anti-HER2 based therapies). Patients with luminal disease showed a statistically significantly longer median PFS than patients with non-luminal disease (10.37 vs. 3.53 months, P = 0.023) and it was concluded that patients with non-luminal disease might not derive a large benefit from this treatment strategy. 66 Another clinical trial investigated the addition of palbociclib with or without trastuzumab in patients with Rb-positive advanced cancer, including a sub-cohort of patients with HER2-amplified disease. Of the 10 patients with HER2-amplified disease receiving palbociclib plus trastuzumab, a response rate of 30% and a PFS of 6.7 months (95% CI 1.6-17.8) was observed.
It was concluded that further investigation into this combination was warranted. 67 Neoadjuvant triplet therapy with trastuzumab, pertuzumab and palbociclib for women with non-metastatic HER2-amplified breast cancer was also investigated (NCT02530424). The primary endpoint was characterization of Ki67 changes from baseline before therapy, at 2 weeks and at surgery. This triplet targeting resulted in a significant and rapid decrease of Ki67 that was of larger magnitude after 2 weeks than at surgery irrespective of the recorded objective clinical response. It was suggested that tolerability and clinical response merit further clinical testing and additional molecular characterization of this chemotherapy-free approach. 68 There are several ongoing clinical trials investigating CDK4/6
inhibitor combinations in patients with advanced HR-positive, HER2-amplified breast cancer (Table 1) . There are two studies evaluating the combination of a CDK4/6 inhibitor with trastuzumab with or without fulvestrant. 69, 70 A phase Ib/II study will test the combination of the novel oral HER2 small molecule inhibitor tucatinib with palbociclib and letrozole as a potential non-chemotherapy based regimen. 71 PATINA (NCT02947685; Table 1 ) is a phase III registration trial investigating the addition of palbociclib to dual HER2-directed (pertuzumab and trastuzumab) and endocrine therapy to determine if the addition of a CDK4/6 inhibitor will prolong PFS compared to dual HER2-directed and endocrine therapy. 72 Similarly, the DETECT V study (NCT02344472 ; Table 1 ) is comparing the safety and efficacy of dual HER2-directed (pertuzumab and trastuzumab) and endocrine therapy with ribociclib. 73 
SUMMARY AND CONCLUSIONS
ER-positivity and HER2-non-amplification are currently the only biomarkers used to select breast cancer patients for treatment with CDK4/6 inhibitors. Further analysis from PALOMA and MONALEESA clinical trials showed response to CDK4/6 inhibitors were not linked to a range of biomarkers from baseline samples. 3, 10, 11, 13, 15 However sequential plasma samples analyzed from the PALOMA-3 trial did show a decrease in PIK3CA ctDNA after 2 weeks strongly predicted for prolonged PFS with palbociclib compared to placebo. 14 
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